| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/06/2005 | CA2530311A1 Cancer treatment with epothilones |
| 01/06/2005 | CA2530228A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/06/2005 | CA2530170A1 Infant formula |
| 01/06/2005 | CA2530125A1 Use of double-stranded ribonucleic acid for inducing cell lysis |
| 01/06/2005 | CA2530113A1 Bioerodible sustained release drug delivery systems |
| 01/06/2005 | CA2530111A1 Glycogen synthase kinase-3 inhibitors |
| 01/06/2005 | CA2530068A1 Cyanoalklamino derivatives useful as cathepsin cysteine protease inhibitors |
| 01/06/2005 | CA2529930A1 Biologically active neopeltolide compounds |
| 01/06/2005 | CA2529873A1 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | CA2529840A1 Therapeutic agent for soft tissue sarcoma |
| 01/06/2005 | CA2529522A1 Methioninase treatment for p.carinii infection |
| 01/06/2005 | CA2529513A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives |
| 01/06/2005 | CA2529468A1 N-{[4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors |
| 01/06/2005 | CA2529447A1 Tablet comprising fluvastatin and carmellose calcium |
| 01/06/2005 | CA2529353A1 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| 01/06/2005 | CA2529227A1 Benzodiazepine cgrp receptor antagonists |
| 01/06/2005 | CA2529151A1 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/06/2005 | CA2529083A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | CA2528785A1 2-amidobenzothiazoles as cb1 receptor inverse agonists |
| 01/06/2005 | CA2528723A1 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | CA2528657A1 Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters |
| 01/06/2005 | CA2528634A1 Treatment of migraine accompanied by nausea |
| 01/06/2005 | CA2528627A1 Treatment of protein aggregation disorders |
| 01/06/2005 | CA2528619A1 Diphenylpyridine derivatives, preparation and therapeutic application thereof |
| 01/06/2005 | CA2528597A1 Stabilized immunomodulatory oligonucleotides |
| 01/06/2005 | CA2528438A1 P-38 inhibitors |
| 01/06/2005 | CA2528347A1 Orally bioavailable low molecular weight metalloporphyrins as antioxidants |
| 01/06/2005 | CA2528155A1 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 01/06/2005 | CA2528152A1 Compositions and methods for treatment of disease with acetylated disaccharides |
| 01/06/2005 | CA2527708A1 Crystalline forms of valacyclovir hydrochloride |
| 01/06/2005 | CA2527659A1 Cyclohexyl derivatives as selective estrogen receptor modulators |
| 01/06/2005 | CA2527284A1 Methods and compositions for modulating serum cortisol levels |
| 01/06/2005 | CA2527079A1 Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| 01/06/2005 | CA2527052A1 Angiogenic agents from plant extracts, gallic acid, and derivatives |
| 01/06/2005 | CA2527019A1 Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| 01/06/2005 | CA2526971A1 Novel dermatological composition |
| 01/06/2005 | CA2526487A1 Heterocyclic methyl sulfone derivative |
| 01/06/2005 | CA2526122A1 Compositions for down-regulation of ccr5 expression and methods of use therefor |
| 01/06/2005 | CA2526085A1 Treatment with anti-vegf antibodies |
| 01/06/2005 | CA2525987A1 Methods of treating hyperproliferative cell disorders |
| 01/06/2005 | CA2525928A1 A method of treating degenerative disc disease |
| 01/06/2005 | CA2525788A1 Anti-adhesion composites and methods of use thereof |
| 01/06/2005 | CA2525589A1 Pancreatic cancer treatment |
| 01/06/2005 | CA2524048A1 Immunosuppressant compounds and compositions |
| 01/06/2005 | CA2522275A1 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 01/06/2005 | CA2522048A1 Methods to mobilize progenitor/stem cells |
| 01/06/2005 | CA2494707A1 Pharmaceutical solid dosage forms exhibiting reproductible drug release profile |
| 01/05/2005 | EP1493825A2 Method for producing nucleic acid ligands |
| 01/05/2005 | EP1493745A1 New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound |
| 01/05/2005 | EP1493744A1 Tropane analogs and methods for inhibition of monoamine transport |
| 01/05/2005 | EP1493743A1 Substituted bipiperidine intermediates and derivatives thereof |
| 01/05/2005 | EP1493742A1 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| 01/05/2005 | EP1493741A2 Benzo[b]thiophene compounds, intermediates, processes, compositions and methods |
| 01/05/2005 | EP1493740A1 5-fluoro-thiophene compounds, the process for their prepartion, the pharmaceutical compositions containing them and their use as metalloproteinases inhibitors |
| 01/05/2005 | EP1493739A1 Thiophene derivatives of aminoacids, process for the preparation thereof and compositions containing them |
| 01/05/2005 | EP1493738A1 Epothilone derivatives |
| 01/05/2005 | EP1493735A1 Pyrimidine derivatives useful as selective cox-2 inhibitors |
| 01/05/2005 | EP1493734A1 Novel crystal form of 5-hydroxy-1-methylhydantoin |
| 01/05/2005 | EP1493732A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 01/05/2005 | EP1493451A1 Hemostatic devices and methods of making same |
| 01/05/2005 | EP1493448A1 Medicinal composition comprising acat inhibitor and insuline resistance improving agent |
| 01/05/2005 | EP1493444A1 Pharmaceutical composition used as anti-infective of the upper respiratory tract |
| 01/05/2005 | EP1493443A1 Use of pyridoxal phosphate for the treatment of diabetes and related complications |
| 01/05/2005 | EP1493442A1 Reboxetine for treating peripheral neuropathy |
| 01/05/2005 | EP1493441A1 Therapeutic agent for food competence disorder in stomach |
| 01/05/2005 | EP1493440A1 Prophylactic agent of hypertension containing a conjugated fatty acid as an effective ingredient and the use thereof |
| 01/05/2005 | EP1493439A1 Means of ascertaining an individual' s risk profile for atherosclerotic disease |
| 01/05/2005 | EP1493438A1 Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| 01/05/2005 | EP1493437A1 Compositions for diabetes |
| 01/05/2005 | EP1493435A1 Controlled Release Compositions of Betahistine |
| 01/05/2005 | EP1492890A2 Large scale methods of producing adenovirus and adenovirus seed stocks |
| 01/05/2005 | EP1492885A2 Schizophrenia associated genes |
| 01/05/2005 | EP1492883A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2) |
| 01/05/2005 | EP1492876A1 Cationic amphiphiles for intracellular delivery of therapeutic molecules, composition, process and use thereof |
| 01/05/2005 | EP1492821A1 Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 01/05/2005 | EP1492817A2 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 01/05/2005 | EP1492803A1 New analogs of nitrobenzylthioinosine |
| 01/05/2005 | EP1492798A1 N-(3-rifamycinyl)-carbamates, method of preparing them and their use for treating and preventing tuberculosis |
| 01/05/2005 | EP1492797A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof |
| 01/05/2005 | EP1492796A1 Substituted amino isoxazoline derivatives and their use as anti-depressants. |
| 01/05/2005 | EP1492795A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 01/05/2005 | EP1492794A1 Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| 01/05/2005 | EP1492793A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives |
| 01/05/2005 | EP1492792A2 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 01/05/2005 | EP1492789A1 Tropane derivatives as ccr5 modulators |
| 01/05/2005 | EP1492788A1 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 01/05/2005 | EP1492787A2 (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them |
| 01/05/2005 | EP1492786A1 Pyridinoylpiperidines as 5-ht1f agonists |
| 01/05/2005 | EP1492785A1 New compounds |
| 01/05/2005 | EP1492784A2 Substituted 2,3-diphenyl pyridines |
| 01/05/2005 | EP1492783A1 4,5,6,7-tretrahydrobenzo(b) thiophene derivatives and methods for medical intervention against mycrobacterial infections |
| 01/05/2005 | EP1492782A1 Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| 01/05/2005 | EP1492781A1 N,n'-disubstituted piperazine compounds and the use of the same as analgesics |
| 01/05/2005 | EP1492780A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| 01/05/2005 | EP1492779A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 01/05/2005 | EP1492778A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors |
| 01/05/2005 | EP1492777A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors |
| 01/05/2005 | EP1492775A2 Oxo-azabicyclic compounds |
| 01/05/2005 | EP1492774A2 Pyrimidone derivatives useful for the treatment of inflammation and immunological diseases |
| 01/05/2005 | EP1492773A2 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |